A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen

* Male and female subjects =/\> 16 years of age (or minimum age required in a given country) with history of chronic hepatitis B infection; * HBeAg negative, anti-HBeAb positive; * Absence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis D virus (HDV); * Absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease; * Less than 12 weeks prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B (e.g., adefovir, famciclovir and lamivudine)